A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at least 400 mg of levodopa daily, tavapadon helped reduce motor ...

Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work equally well for everyone. By mapping patients’ brain signals before and ...

Researchers have used magnetoencephalography brain imaging technology to determine how the drug levodopa, the main drug used ...

Simon Fraser University researchers are pioneering personalized Parkinson's treatment using MEG imaging. They discovered that ...

Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors — has been linked to side effects including sleep disorders, hallucinations, impulse ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an analysis of RHHBY stock now.

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational Parkinson’s disease treatment prasinezumab into Phase 3 trials. The company ...

HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total ...

Expert Rev Neurother. 2009;9(7):929-940. Improvements in levodopa pharmacokinetics with the addition of entacapone were similar to that seen in healthy volunteers. In addition, Phase II trials ...